AbbVie (NYSE:ABBV) Stock Price Up 4.2% – Here’s What Happened

Shares of AbbVie Inc. (NYSE:ABBV) rose 4.2% during trading on Thursday . The company traded as high as $254.54 and last traded at $254.2920. 6,240,800 shares changed hands during trading, a decline of 13% from the average daily volume of 7,156,321 shares. The stock had previously closed at $244.11.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of research reports. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. UBS Group increased their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday. Bank of America raised their target price on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Wells Fargo & Company lifted their price target on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, July 10th. Finally, HSBC reiterated a “buy” rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $267.67.

AbbVie Stock Performance

The company has a market cap of $449.70 billion, a PE ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30. The firm’s 50 day moving average is $229.80 and its 200-day moving average is $221.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, analysts predict that AbbVie Inc. will post 14.16 EPS for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Institutional Trading of AbbVie

Large investors have recently added to or reduced their stakes in the stock. Willner & Heller LLC grew its holdings in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the last quarter. Bank of Jackson Hole Trust lifted its holdings in shares of AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after purchasing an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV boosted its position in shares of AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after purchasing an additional 45 shares during the period. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares during the period. Finally, Hardin Capital Partners LLC increased its stake in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after purchasing an additional 46 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.